See what we are up to

MetaLead is developing short peptides that could vastly improve the state of selective chelation therapy, being safer and more potent in human cells and model animals. The novel short peptides bind toxic metals like lead while not binding metals essential to the metabolism, such as calcium and zinc, making them safe for children and pregnant women treated for high levels of metal poisoning.

The physical health burden of endometriosis can cause infertility and lead to hysterectomy for up to 20% of affected women. However, only one new treatment was approved for the disease in the past decade. Endometriosis' impact reverberates through the healthcare system, economy, and society as millions of women suffer and the direct and indirect costs continue to mount. To address this unmet medical need, FimmCyte has engineered a first-in-class, disease-modifying treatment that has shown efficacy in eliminating endometriosis in the lab and animal models. FimmCyte will use the CHF 150,000 Venture Kick award to advance their lead candidate through preclinical regulatory requirements to pave the way for the first-in-human trial within the next few years.

MassChallenge Switzerland announces 2022 Cohort. MassChallenge’s global network of innovators announced the 100 early-stage startups invited to join the 2022 Program. This number represents the Top 9% of applications received from around the world.

MetaLead, a research group of the University of Zurich, developing small molecule drugs to detoxify toxic metals wins 10’000 CHF.

In this episode of BioInnovation Spotlight, Simon tells us the story of how an HIV research model led him to pursue cancer treatment and the potential impact these cells could have in cell therapy treatments for hard-to-treat cancers like Triple Negative Breast Cancer.

FimmCyte admitted as early Start up to 2022 program.

Novel methods for non invasive imaging or amyloid Beta and tau in animals models or Alzheimer’s disease published using optoacoustic tomography at 10 times better resolution than conventional small animal PET to better measure changes over time.